AR049112A1 - Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual - Google Patents
Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrualInfo
- Publication number
- AR049112A1 AR049112A1 ARP050102132A ARP050102132A AR049112A1 AR 049112 A1 AR049112 A1 AR 049112A1 AR P050102132 A ARP050102132 A AR P050102132A AR P050102132 A ARP050102132 A AR P050102132A AR 049112 A1 AR049112 A1 AR 049112A1
- Authority
- AR
- Argentina
- Prior art keywords
- progestin
- levonorgestrel
- estrogen
- dysphoric disorder
- premenstrual dysphoric
- Prior art date
Links
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 5
- 239000000583 progesterone congener Substances 0.000 abstract 5
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 3
- 229940011871 estrogen Drugs 0.000 abstract 3
- 239000000262 estrogen Substances 0.000 abstract 3
- 229960004400 levonorgestrel Drugs 0.000 abstract 3
- 239000002552 dosage form Substances 0.000 abstract 2
- -1 signodena Chemical compound 0.000 abstract 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 abstract 1
- ISHXLNHNDMZNMC-VTKCIJPMSA-N (3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C\1 ISHXLNHNDMZNMC-VTKCIJPMSA-N 0.000 abstract 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 abstract 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 abstract 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229960001616 chlormadinone acetate Drugs 0.000 abstract 1
- 229960000978 cyproterone acetate Drugs 0.000 abstract 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 abstract 1
- 229960004976 desogestrel Drugs 0.000 abstract 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 abstract 1
- 229960001348 estriol Drugs 0.000 abstract 1
- 229960003399 estrone Drugs 0.000 abstract 1
- 229960002568 ethinylestradiol Drugs 0.000 abstract 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 abstract 1
- 229960001390 mestranol Drugs 0.000 abstract 1
- 229960002667 norelgestromin Drugs 0.000 abstract 1
- 229960001652 norethindrone acetate Drugs 0.000 abstract 1
- 229960000417 norgestimate Drugs 0.000 abstract 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Un método para tratar una paciente que sufre de trastorno disforico premenstrual que comprende administrar una cantidad efectiva de al menos una progestina y al menos un estrogeno a dicho paciente, en donde dicha cantidad efectiva se administra diariamente durante al menos 100 días. Dicho método en donde se administra 4microgramos de levonorgestrel, o una dosis de progestina de igual potencia, y en donde la progestina es acetato de clormadinona, acetato de noretisterona, acetato de ciproterona, desogestrel, gestodena, drospirenona, etonorgestrel, norgestimato, norelgestromin o levonorgestrel. Dicho estrogeno es etinil estradiol, mestranol, estradiol, estriol, estrona o estrano. Un conjunto para tratar a una paciente que comprende al menos 100 formas de dosis que individualmente comprenden al menos una progestina y al menos un estrogeno. Dicho conjunto en donde cada una de las formas de dosis comprende al menos 4 microgramos de levonorgestrel o forma de dosis de progestina de igual potencia, y en donde las formas de dosis son tabletas, cápsulas, o una combinacion de ambas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57465104P | 2004-05-26 | 2004-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049112A1 true AR049112A1 (es) | 2006-06-28 |
Family
ID=34969878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102132A AR049112A1 (es) | 2004-05-26 | 2005-05-24 | Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050272712A1 (es) |
| EP (1) | EP1755618A1 (es) |
| JP (1) | JP2008500340A (es) |
| CN (1) | CN1972692A (es) |
| AR (1) | AR049112A1 (es) |
| AU (1) | AU2005249401A1 (es) |
| BR (1) | BRPI0511569A (es) |
| CA (1) | CA2566811A1 (es) |
| GT (1) | GT200500127A (es) |
| MX (1) | MXPA06013418A (es) |
| PE (1) | PE20060275A1 (es) |
| TW (1) | TW200602063A (es) |
| WO (1) | WO2005117898A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| TW200726473A (en) * | 2005-06-28 | 2007-07-16 | Wyeth Corp | Compositions and methods for treatment of cycle-related symptoms |
| JP2013504531A (ja) * | 2009-09-11 | 2013-02-07 | バイエル・ファルマ・アクチェンゲゼルシャフト | 抗癌薬としての置換（ヘテロアリールメチル）チオヒダントイン |
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| DE102019115343A1 (de) * | 2019-06-06 | 2020-12-10 | EVESTRA GmbH | Vaginalring für die hormonelle Kontrazeption |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291014A (en) * | 1979-01-11 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing estradiol diacetate |
| US4438139A (en) * | 1979-08-14 | 1984-03-20 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing estrogens |
| US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
| JPS60174716A (ja) * | 1984-02-21 | 1985-09-09 | Yamanouchi Pharmaceut Co Ltd | パツチ剤 |
| US4752478A (en) * | 1984-12-17 | 1988-06-21 | Merck & Co., Inc. | Transdermal system for timolol |
| US4855305A (en) * | 1987-03-23 | 1989-08-08 | Applied Medical Research | Compositions and methods of effecting contraception utilizing melatonin |
| DE19654609A1 (de) * | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder |
| CA2468748C (en) * | 2001-12-05 | 2010-01-26 | Barr Laboratories, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| DK1635843T3 (da) * | 2003-06-25 | 2009-05-04 | Bayer Schering Pharma Ag | Terapi, der omfatter dienogest for hormonerstatning og depression |
-
2005
- 2005-05-09 CN CNA2005800153947A patent/CN1972692A/zh active Pending
- 2005-05-09 WO PCT/US2005/016180 patent/WO2005117898A1/en not_active Ceased
- 2005-05-09 BR BRPI0511569-8A patent/BRPI0511569A/pt not_active IP Right Cessation
- 2005-05-09 EP EP05746668A patent/EP1755618A1/en not_active Withdrawn
- 2005-05-09 MX MXPA06013418A patent/MXPA06013418A/es unknown
- 2005-05-09 AU AU2005249401A patent/AU2005249401A1/en not_active Withdrawn
- 2005-05-09 JP JP2007515131A patent/JP2008500340A/ja not_active Withdrawn
- 2005-05-09 CA CA002566811A patent/CA2566811A1/en not_active Abandoned
- 2005-05-24 GT GT200500127A patent/GT200500127A/es unknown
- 2005-05-24 PE PE2005000575A patent/PE20060275A1/es not_active Application Discontinuation
- 2005-05-24 TW TW094116889A patent/TW200602063A/zh unknown
- 2005-05-24 AR ARP050102132A patent/AR049112A1/es unknown
- 2005-05-26 US US11/138,747 patent/US20050272712A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2566811A1 (en) | 2005-12-15 |
| JP2008500340A (ja) | 2008-01-10 |
| US20050272712A1 (en) | 2005-12-08 |
| PE20060275A1 (es) | 2006-05-26 |
| TW200602063A (en) | 2006-01-16 |
| CN1972692A (zh) | 2007-05-30 |
| MXPA06013418A (es) | 2007-01-23 |
| WO2005117898A1 (en) | 2005-12-15 |
| EP1755618A1 (en) | 2007-02-28 |
| GT200500127A (es) | 2006-03-23 |
| AU2005249401A1 (en) | 2005-12-15 |
| BRPI0511569A (pt) | 2008-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049112A1 (es) | Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual | |
| RU2122854C1 (ru) | Комбинированный препарат для контрацепции, фармацевтическая упаковка для контрацепции | |
| US20050113350A1 (en) | Extended use combination comprising estrogens and progestins | |
| US20080234240A1 (en) | Extended Use Combination Comprising Estrogens And Progestins | |
| RU2009120528A (ru) | Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла | |
| RU2007148080A (ru) | Составы и способы для лечения симптомов, связанных с циклом | |
| JP2019163318A5 (es) | ||
| JP2010508275A5 (es) | ||
| JP2013514984A5 (es) | ||
| JP2007535519A5 (es) | ||
| ATE356635T1 (de) | Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen | |
| JP2005516913A5 (es) | ||
| AR016502A1 (es) | Uso de sulfamatos estrogenos biogenicos en una terapia de reemplazo de hormonas. | |
| AR049197A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
| ES2348038T5 (es) | Preparado polifásico para la contracepción sobre la base de un estrógeno natural | |
| EP1286666B1 (en) | Starter kit for low dose oral contraceptives | |
| RU2000115313A (ru) | Схемы приема гестаген-анти-гестагена | |
| EA200701389A1 (ru) | Твёрдая пероральная лекарственная форма для контрацепции | |
| BE1027858B1 (fr) | Composition pharmaceutique pour la contraception chez la femme | |
| MX2007009061A (es) | Preparacion farmaceutica para la anticoncepcion oral. | |
| WO2022076733A1 (en) | Cyproterone acetate compositions and uses thereof | |
| CY1112775T1 (el) | Χρηση βαλεριανικης οιστραδιολης σε συνδυασμο με dienogest για την απο του στοματος θεραπεια της δυσλειτουργικης αιμορραγιας της μητρας σε ενοτητα με αντισυλληψη απο του στοματος | |
| RU2008149412A (ru) | Применение дроспиренона для предотвращения высокого кровяного давления у пациентов с прегипертонией | |
| US20080280861A1 (en) | Method of Female Contraception and a Kit For Use Therein | |
| AU4120400A (en) | Use of antiprogestagens in combined therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |